ID: ALA4168126

Max Phase: Preclinical

Molecular Formula: C21H30N4

Molecular Weight: 338.50

Molecule Type: Small molecule

Representations

Canonical SMILES:  C[C@@H](c1ccccn1)N(CCCCN)C[C@H]1Cc2ccccc2CN1

Standard InChI:  InChI=1S/C21H30N4/c1-17(21-10-4-6-12-23-21)25(13-7-5-11-22)16-20-14-18-8-2-3-9-19(18)15-24-20/h2-4,6,8-10,12,17,20,24H,5,7,11,13-16,22H2,1H3/t17-,20+/m0/s1

Standard InChI Key:  MEPBMCYDMSNDHL-FXAWDEMLSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 338.50

Molecular Weight (Monoisotopic): 338.2470

AlogP: 2.90

#Rotatable Bonds: 8

Polar Surface Area: 54.18

Molecular Species: BASE

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 10.22

CX LogP: 2.59

CX LogD: -1.49

Aromatic Rings: 2

Heavy Atoms: 25

QED Weighted: 0.73

Np Likeness Score: -0.37

References

1. Wilson RJ, Jecs E, Miller EJ, Nguyen HH, Tahirovic YA, Truax VM, Kim MB, Kuo KM, Wang T, Sum CS, Cvijic ME, Paiva AA, Schroeder GM, Wilson LJ, Liotta DC..  (2018)  Synthesis and SAR of 1,2,3,4-Tetrahydroisoquinoline-Based CXCR4 Antagonists.,  9  (1): [PMID:29348805] [10.1021/acsmedchemlett.7b00381]

Source

Source(1):

• Scientific Literature